The most innovative longevity research could bag 50k CHF thanks to Maximon, which is launching its first Prize for Translational Research in Longevity.
Switzerland-based Maximon, Europe’s first longevity company builder, is launching the Maximon Longevity Prize for Translational Research, awarding breakthrough research in the field of longevity that has the potential to substantially increase the healthspan or lifespan of humans. Maximon has pledged 50,000 CHF for the winner of the prize and is committed to attracting more donors and sponsors to further support the cause.
Longevity.Technology: Two of Maximon’s founding partners, Marc Bernegger and Dr Tobias Reichmuth, are the driving force behind the now annual Longevity Investors Conference, and Maximon also launched the 100 CHF million Longevity Co-Investment Fund, empowering entrepreneurs to build impactful, science-based and scalable companies that provide healthy aging and rejuvenation solutions. Today’s announcement sees the successful company-builder continuing to commit funding to bridging the gap between science and business.
Two of Maximon’s ventures have also pledged exclusive rewards for the prize recipient: longevity advisory and big data company Biolytica will provide a personalised longevity concierge program to the value of 20,000 CHF, and longevity supplement company AVEA will supply the winner with a one-year subscription for its science-based longevity supplements to the value of 5,000 CHF.
The prize is open to applications from all academic/non-profit researchers, inventors, scientists, students or start-up founders who either published their breakthrough research, hold the patent or are in very advanced stages of research. The application window will be open for six months, starting on the 1st of March until the 31st of July 2022.
“We are on a mission to extend the human health-span helping people to stay fit, healthy, and happy until old age. We believe that supporting bold breakthrough ideas and the scientists behind them is much needed to speed-up the translation of science to products and services available to everyone,” says Dr Tobias Reichmuth, Founding Partner of Maximon.
“With this prize, we are hoping to bridge the gap between science and clinic and give exceptional researchers the resources they need to expand their work and accelerate their research to find interventions for a longevity society,” adds Dr Ashish Rajput, Chief Scientific Officer at Maximon and member of the Jury Committee of the prize.
Other members of the Jury include Professor Brian Kennedy, Distinguished Professor, Department of Biochemistry and Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Prof Collin Ewald, Assistant Professor at ETH Zurich.
The evaluation phase will take place in August 2022 and will culminate with a presentation of the top 3 finalists during the Longevity Investors Conference (LIC), taking place on September 28-30 at Le Grand Bellevue Hotel in Gstaad, Switzerland. The conference is the world’s leading and most private investors-focused conference in the field of longevity. The LIC brings together the most renowned longevity scientists, private and institutional investors, and family offices. The winner will be announced during a prize ceremony at the LIC Gala Dinner taking place on September 29 in Le Grand Bellevue Hotel, Gstaad.